Distribution of average relative amounts of lipid classes. by Spela Kokelj (8356644)

Subjects:

Flow chart on the inclusion and drop out of patients. by Spela Kokelj (8356644)

Subjects:

Differentially abundant lipid species in COVID-19 cases at baseline and at follow-up as compared to healthy controls. by Spela Kokelj (8356644)

Subjects:

Symptoms reported by COVID-19 cases at baseline and at follow-up. by Spela Kokelj (8356644)

Subjects:

Loss of life expectancy that would result if colorectal cancer missed in 2011 had been diagnosed in 2011 (unit: years). by Hiroaki Saito (24514)

Subjects:

Estimated detected and non-detected colorectal cancer rates and their clinical stages based on colorectal cancer screening in Minamisoma City in 2011. by Hiroaki Saito (24514)

Subjects:

Conceptual diagram of survival curve and loss of life expectancy. by Hiroaki Saito (24514)

Subjects:

Loss of life expectancy by age group and stage of colorectal cancer and change if detected after one year. by Hiroaki Saito (24514)

Subjects:

Estimated distribution of colorectal cancer stage among patients assumed to have missed diagnosis in 2011 (unit: persons). by Hiroaki Saito (24514)

Subjects:

Additional loss of life expectancy and cost per life-year saved resulting from changes in colorectal cancer stage due to a 1-year diagnostic delay. by Hiroaki Saito (24514)

Subjects:

Centrifuged FMT products consistently exhibit the lowest median log₁₀ drop of CFU/g following freezing and lyophilization. In contrast, unprocessed feces exhibited the g... by Nina K. Randolph (21030732)

Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras by Charles W. Parry (20966154)

Original CFU counts per sample. by Annika L. Gilmore (20700654)

Subjects:

Representative images of <i>S. aureus</i> biofilm grown on CDC Biofilm Reactor® coupons and 4 mm diameter glass beads. by Annika L. Gilmore (20700654)

Subjects:

Biofilm bead reactor for low shear, high-throughput growth of biofilms on 50 substrates. by Annika L. Gilmore (20700654)

Subjects:

<i>P. aeruginosa</i> bioburden reduction in log₁₀ CFU per mm². by Annika L. Gilmore (20700654)

Subjects:

MIC of ertapenem, moxifloxacin, and tobramycin against <i>S. aureus</i> and <i>P. aeruginosa.</i> by Annika L. Gilmore (20700654)

Subjects:

Representative images of <i>P. aeruginosa</i> biofilm grown on glass coupons and beads. by Annika L. Gilmore (20700654)

Subjects:

Standardized BioSurface Technologies CDC Biofilm Reactor® for dynamic, high-shear biofilm growth on 24 coupons. by Annika L. Gilmore (20700654)

Subjects:

Median recovery efficiency (%R) using either the face or edge on each organism’s SP optimum area or the WT method. by Monica Y. Chan-Riley (20148171)